Leerink Partnrs Issues Optimistic Estimate for SPRY Earnings

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of ARS Pharmaceuticals in a report issued on Sunday, June 22nd. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.42) per share for the quarter, up from their previous estimate of ($0.43). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Leerink Partnrs also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($0.60) EPS, FY2027 earnings at $0.56 EPS and FY2028 earnings at $2.67 EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). ARS Pharmaceuticals had a negative net margin of 16.11% and a negative return on equity of 6.94%. The business had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million.

Several other research analysts have also recently issued reports on the stock. Scotiabank began coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price for the company. William Blair reiterated an "outperform" rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Finally, Wall Street Zen upgraded shares of ARS Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $31.00.

ARS Pharmaceuticals Stock Up 0.7%

Shares of ARS Pharmaceuticals stock traded up $0.12 during trading hours on Wednesday, hitting $18.20. The company had a trading volume of 3,883,996 shares, compared to its average volume of 1,338,171. The company's 50-day moving average is $14.63 and its two-hundred day moving average is $13.02. ARS Pharmaceuticals has a twelve month low of $8.02 and a twelve month high of $18.90. The company has a debt-to-equity ratio of 0.30, a current ratio of 11.00 and a quick ratio of 10.74. The company has a market cap of $1.79 billion, a P/E ratio of -113.74 and a beta of 0.84.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Alliancebernstein L.P. grew its stake in shares of ARS Pharmaceuticals by 5,168.4% during the 4th quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock worth $40,942,000 after purchasing an additional 3,807,074 shares during the period. MPM Bioimpact LLC purchased a new stake in ARS Pharmaceuticals during the first quarter worth about $16,519,000. Alyeska Investment Group L.P. grew its position in ARS Pharmaceuticals by 903.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock worth $13,227,000 after buying an additional 1,128,724 shares during the period. Cormorant Asset Management LP increased its holdings in ARS Pharmaceuticals by 220.0% in the first quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock valued at $20,128,000 after buying an additional 1,100,000 shares in the last quarter. Finally, Aberdeen Group plc purchased a new position in ARS Pharmaceuticals in the first quarter valued at about $12,613,000. Hedge funds and other institutional investors own 68.16% of the company's stock.

Insider Activity at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 102,969 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $14.10, for a total transaction of $1,451,862.90. Following the completion of the transaction, the insider now directly owns 89,613 shares of the company's stock, valued at approximately $1,263,543.30. This represents a 53.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Laura Shawver sold 50,002 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The shares were sold at an average price of $12.30, for a total value of $615,024.60. Following the completion of the sale, the director now directly owns 210,346 shares of the company's stock, valued at $2,587,255.80. This represents a 19.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 337,971 shares of company stock worth $4,721,888 in the last 90 days. 33.50% of the stock is owned by insiders.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.